Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NRX Pharmaceuticals (NRXP) Non-Current Assets (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Non-Current Assets for 2 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 1064.47% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, up 402.94% year-over-year, with the annual reading at $4.1 million for FY2025, 1064.47% up from the prior year.
  • Non-Current Assets for Q4 2025 was $4.1 million at NRX Pharmaceuticals, up from $3.0 million in the prior quarter.
  • The five-year high for Non-Current Assets was $4.1 million in Q4 2025, with the low at $248000.0 in Q2 2025.